Păun Ion, Becheanu Gabriel, Costin Andrei Ionuţ, Constantin Vlad Denis, Mihai Gabriela Marcelina, Radu Lucreţiu, Iovan Larisa, Vârcuş Flore
Department of Surgery, University of Medicine and Pharmacy of Craiova, Surgery Unit, Railway Clinical Hospital, Craiova, Romania;
Rom J Morphol Embryol. 2018;59(3):673-678.
Neuroendocrine neoplasms (NENs) of the digestive system are composed of cells with a neuroendocrine phenotype. These tumors produce and secrete peptide hormones and biogenic amines and they are called neuroendocrine neoplasms because of the marker proteins that they share with the neural cell system. The classification and nomenclature used to designate NENs have undergone changes over the past decades due to the accumulation of evidence related to the biological characteristics and their evolution. The European Neuroendocrine Tumor Society (ENETS) proposed a classification system based on the tumor grading and staging according to their localization. The latest internationally recognized NEN classification was published by the World Health Organization (WHO) in 2010. In accordance with the 2010 WHO criteria, the determination of the NEN malignancy potential is based on grading, depending on the mitotic activity and the Ki67 proliferation index, as well as on the tumor TNM stage. It is worth emphasizing that the terms neuroendocrine tumor (NET) and neuroendocrine carcinoma (NEC), without reference to grading or differentiation, are inadequate for prognostic assessment or the therapy determination, being inappropriate in pathology reports. The functional status of the tumor is based on the clinical findings but not on the pathological data or immunohistochemically profile. Despite the inability to establish a single system of sites, these are common features to establish the basis of most systems, documentation of these features allowing for greater reliability in the pathology reporting of these neoplasms.
消化系统神经内分泌肿瘤(NENs)由具有神经内分泌表型的细胞组成。这些肿瘤产生并分泌肽类激素和生物胺,由于它们与神经细胞系统共享标记蛋白,因此被称为神经内分泌肿瘤。过去几十年来,由于与生物学特征及其演变相关的证据不断积累,用于命名NENs的分类和术语发生了变化。欧洲神经内分泌肿瘤学会(ENETS)根据肿瘤的定位,提出了一种基于肿瘤分级和分期的分类系统。世界卫生组织(WHO)于2010年发布了最新的国际认可的NEN分类。根据2010年WHO标准,NEN恶性潜能的确定基于分级,取决于有丝分裂活性和Ki67增殖指数,以及肿瘤TNM分期。值得强调的是,神经内分泌肿瘤(NET)和神经内分泌癌(NEC)这两个术语,在未提及分级或分化的情况下,不足以用于预后评估或治疗确定,在病理报告中是不合适的。肿瘤的功能状态基于临床发现,而非病理数据或免疫组化特征。尽管无法建立单一的部位系统,但这些是大多数系统的共同特征,记录这些特征可提高这些肿瘤病理报告的可靠性。